Loading...
XASX
OSL
Market cap21mUSD
Sep 17, Last price  
0.97AUD
1D
-0.51%
1Q
22.01%
Jan 2017
1,027.91%
IPO
440.03%
Name

Oncosil Medical Ltd

Chart & performance

D1W1MN
XASX:OSL chart
P/E
—
P/S
17.78
EPS
—
Div yield, %
—
Shrs. gr., 5y
-53.83%
Rev. gr., 5y
51.22%
Revenues
2m
+43.92%
1,758,0002,064,0002,303,0002,087,124000315,8572,757,0003,837,0003,514,0004,448,0003,626,0002,764,000213,070231,789367,677516,6321,170,7931,684,978
Net income
-11m
L-28.08%
-1,674,000-2,767,000-440,000-1,712,021-1,458,000-431,000-879,000-6,865,000-2,879,000-4,769,000-7,016,000-8,540,000-8,567,000-4,262,000-10,434,000-10,727,000-11,343,000-11,914,000-15,099,844-10,860,122
CFO
-10m
L-13.18%
-1,345,466-2,180,247-103,974154,348-316,665-305,783-471,908-6,369,942-171,159-4,572,568-6,109,845-8,397,341-7,501,154-4,456,079-8,815,401-10,110,178-11,315,634-10,824,337-12,062,301-10,472,438

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

Key people

Chris Roberts
Non-Executive Chairman of the Board · since 2017
Nicholas Falzon
Chief Financial Officer, Company Secretary · since 2019
Martin George Cross
Director · since 2017
Daniel Kenny
Chief Executive Officer, Director · since 2015
Michael John Bassett
Non-Executive Director · since 2018
URL
http://www.oncosil.com.au/
IPO date
Aug 15, 2005
Employees
2
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT